Uncategorized

Pfizer and Arvinas give disappointing breast cancer drug to Rigel

Published

on

Pfizer has turned $1 billion into $35 million.

The New York-based pharma company and its partner Arvinas are selling rights to their recently approved breast cancer drug to Rigel Pharmaceuticals. They decided last year that …

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version